These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
791 related articles for article (PubMed ID: 33152946)
1. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells. Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946 [TBL] [Abstract][Full Text] [Related]
2. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy. Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211 [TBL] [Abstract][Full Text] [Related]
3. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain. Svarcbahs R; Julku UH; Myöhänen TT J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963 [TBL] [Abstract][Full Text] [Related]
5. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220 [TBL] [Abstract][Full Text] [Related]
6. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture. Myöhänen TT; Norrbacka S; Savolainen MH Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354 [TBL] [Abstract][Full Text] [Related]
7. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model. Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers. Dokleja L; Hannula MJ; Myöhänen TT Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592 [TBL] [Abstract][Full Text] [Related]
10. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy. Cui H; Norrbacka S; Myöhänen TT Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496 [TBL] [Abstract][Full Text] [Related]
18. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model. Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679 [TBL] [Abstract][Full Text] [Related]
19. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. Rostami J; Mothes T; Kolahdouzan M; Eriksson O; Moslem M; Bergström J; Ingelsson M; O'Callaghan P; Healy LM; Falk A; Erlandsson A J Neuroinflammation; 2021 Jun; 18(1):124. PubMed ID: 34082772 [TBL] [Abstract][Full Text] [Related]
20. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein. Ho DH; Seol W; Son I Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]